News & Opinion
Top 10 Innovations
Cell & Molecular Biology
Disease & Medicine
Ecology & Environment
Genetics & Genomics
Pharma & Biotech
Image of the Day
CAR T cells
CAR T cells
Researchers Build a Cancer Immunotherapy Without Immune Cells
Abby Olena | Nov 13, 2017
A team has engineered two stem cell lines into “synthetic T cells” that destroy breast cancer cells in vitro.
FDA Approves Second CAR T-Cell Therapy
Ashley P. Taylor | Oct 19, 2017
The therapy, produced by Kite Pharma and owned by Gilead Sciences, is approved for use against some types of large B-cell lymphomas.
First CAR T-Cell Therapy Approved in U.S.
Shawna Williams | Aug 30, 2017
The genetically modified blood cells will be used for patients with a type of acute lymphoblastic leukemia, when other treatments fail.
Gilead to Pay Nearly $12B for CAR T-Cell Company
Jef Akst | Aug 28, 2017
The massive sum will buy out Kite Pharma, whose cancer therapy is expected to be among the first of its type approved by the FDA.
The Ever-Expanding T-Cell World: A Primer
Ashley P. Taylor | Aug 7, 2017
Researchers continue to identify new T-cell subtypes—and devise ways to use them to fight cancer.
attempts to catalog them all.
FDA Votes Yes on CAR T-Cell Therapy
Aggie Mika | Jul 13, 2017
A Food and Drug Administration advisory panel unanimously calls for agency approval of the cell therapy for the treatment of resistant leukemia.
CAR T-Cell Trials Boast Promising Results
Diana Kwon | Jun 5, 2017
The results of two small clinical trials show that the immunotherapy is effective for multiple myeloma patients, at least in the near term.
Hitting It Out of the Park
Mary Beth Aberlin | Apr 1, 2017
Cancer can be as evasive and slippery as a spitball, but new immunotherapies are starting to connect.
Making CAR T-Cell Therapy Safer
Catherine Offord | Apr 1, 2017
Following a spate of patient deaths in clinical trials testing modified T cells for the treatment of cancer, researchers work to reduce the treatment’s toxicity without sacrificing efficacy.
Kite’s CAR T-Cell Therapy Success
Jef Akst | Mar 1, 2017
More than one-third of lymphoma patients in a Phase 2 trial were clear of disease at six months, and no new safety concerns arose since the company’s three-month follow up.